In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

ESC/EACTS Guidelines for the management of valvular heart disease published today

Valvular Heart Diseases


Barcelona, Spain – 26 Aug 2017: European Society of Cardiology (ESC) / European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular heart disease are published online today in European Heart Journal (1) and on the ESC website. (2)

“Since the 2012 Guidelines a large amount of new data have accumulated, particularly in the field of catheter interventional treatment of valvular heart disease,” said Prof Helmut Baumgartner, ESC Chairperson (Germany). “In aortic stenosis, there have been five randomised clinical trials comparing surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) as well as large-scale registry data.”

“There is also new evidence regarding predictors of outcome in asymptomatic patients with valvular heart disease and on antithrombotic therapy in this patient population among other innovations,” he continued. “This definitely required an update of management recommendations.”

“We have now expanded the indications for transcatheter valves because there is new evidence in the intermediate risk population,” said Prof Volkmar Falk, EACTS Chairperson (Germany).

Regarding the decision between SAVR and TAVI for symptomatic aortic stenosis, the guidelines emphasise that it should be made by a heart team of surgeons and cardiologists. A new recommendation is that both procedures should be performed in a heart valve centre which has departments for cardiac surgery and cardiology providing structured collaboration on site, conducts structured training, records data on performance and patient outcomes, and participates in registries.

Broadly speaking, patients at high risk for surgery should receive TAVI and those at low risk (especially younger patients) should undergo SAVR.

But Prof Baumgartner said: “The choice of SAVR or TAVI is not simply based on a risk score or age. The heart team must weigh the risks and benefits of both procedures, particularly in the intermediate risk situation. Discussion should include age, comorbidities, anatomy, and outcomes of the centre for surgery and transcatheter intervention.”

“Evidence is based on trials in patients with a mean age of 80 years and the recommendations cannot be applied to those below 70 to 75 years,” continued Prof Baumgartner. “Younger patients have more bicuspid valves, which may have worse TAVI results than tricuspid valves, and there is no long-term data on the durability of TAVI valves. Complications such as paravalvular leakage or need for a pacemaker are still more frequent with TAVI compared to surgery which is important in younger patients with a longer life expectancy. In younger patients there must still be a critical risk of surgery before considering TAVI.”

In asymptomatic patients with valve disease studies suggested that early surgery may improve outcomes, but deciding when to intervene remains controversial. As examples, pulmonary hypertension has been introduced into the criteria for selecting asymptomatic aortic stenosis patients for surgery following studies showing it was a predictor of poor outcomes. Conflicting studies on the prognostic value of exercise echocardiographic parameters resulted, on the other side, in their removal from the selection criteria for asymptomatic patients with aortic stenosis and mitral regurgitation.

In the area of antithrombotic therapy, there is now sufficient data to recommend non-vitamin K antagonist oral anticoagulants (NOACs) as an alternative to vitamin K antagonists in atrial fibrillation patients with aortic valve disease or mitral regurgitation. NOACs remain, however, contraindicated in patients with mechanical valves and in mitral stenosis.

Prof Falk said: “This is a joint guideline between cardiologists and surgeons. It is absolutely essential that both specialties follow the same recommendations because we are treating the same patients. Decisions in structural valve disease must be taken by a heart team of cardiologists and surgeons.”

The document is shorter than conventional guidelines and those wanting more information can consult the updated chapter on valvular heart disease in the ESC Textbook of Cardiology, which was written by the same team. The linkage between these two documents is being piloted and its acceptance by users will be evaluated by the ESC.

ENDS

Notes to editor

Sources of funding: None.

Disclosures: The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website: www.escardio.org/guidelines

References:
(1) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2017. doi: 10.1093/eurheartj/ehx391
(2) ESC Guidelines on the ESC website: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Valvular-Heart-Disease-Management-of

Guidelines at ESC Congress
The Valvular Heart Disease Guidelines will be featured in:
• ESC Guidelines 2017 – Overview on 27 August at 08:30
• ESC Guidelines 2017 – Valvular Heart Disease on 28 August at 08:30
• Meet the Guidelines Task Force – Valvular Heart Disease on 29 August at 16:00
• Congress Condensed – ESC Clinical Practice Guidelines 2017 on 30 August at 09:00

Associated Derivative Products can be found via the ESC website at:
https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-derivative-products
Download the free ESC Pocket Guidelines App for all mobile devices: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-derivative-products/ESC-Mobile-Pocket-Guidelines


ESC Press Office
For more information, please contact the ESC Press Office: press@escardio.org.
For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856

The press conference timetable is available here.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365

About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2017
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org.